Cargando…

Co-Administration with Voriconazole Doubles the Exposure of Ruxolitinib in Patients with Hematological Malignancies

BACKGROUND: Ruxolitinib is newly approved for glucocorticoid-refractory acute graft-versus-host disease (GVHD) in patients undergoing allo-geneic hematopoietic stem-cell transplantation (allo-HSCT), and voriconazole is commonly used in allo-HSCT recipients for the prophylaxis or treatment of invasiv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Yingxin, Chen, Peng, Dou, Liping, Li, Fei, Li, Meng, Xu, Lingmin, Chen, Jing, Jia, Mingyu, Huang, Sai, Wang, Nan, Luan, Songhua, Yang, Jinling, Bai, Nan, Liu, Daihong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8964335/ https://www.ncbi.nlm.nih.gov/pubmed/35370398 http://dx.doi.org/10.2147/DDDT.S354270

Ejemplares similares

Ruxolitinib-corticosteroid as first-line therapy for newly diagnosed high-risk acute graft versus host disease: study protocol for a multicenter, randomized, phase II controlled trial
por: Dou, Liping, et al.
Publicado: (2022)

Elevated REG3α predicts refractory aGVHD in patients who received steroids-ruxolitinib as first-line therapy
por: Yang, Jingjing, et al.
Publicado: (2021)

Serum voriconazole level variability in patients with hematological malignancies receiving voriconazole therapy
por: Saini, Lalit, et al.
Publicado: (2014)

Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies
por: Dou, Liping, et al.
Publicado: (2021)

755. Posaconazole versus voriconazole as antifungal prophylaxis for invasive fungal diseases in patients with hematological malignancies
por: Almutairy, Reem F, et al.
Publicado: (2020)

Association of Voriconazole Trough Plasma Concentration with Efficacy and Incidence of Hepatotoxicity in Iranian Patients with Hematological Malignancies
por: Taghvaye-masoumi, Hamidreza, et al.
Publicado: (2021)

S247: ADDING RUXOLITINIB AND DECITABINE TO BU/CY CONDITIONING REGIMENS TO PROPHYLAXIS POST-TRANSPLANT RELAPSE IN HIGH-RISK AML IS SAFE AND EFFECTIVE: A PROSPECTIVE, PHASE II STUDY
por: Wei, Yujun, et al.
Publicado: (2023)

Reduced risk of chronic GVHD by low-dose rATG in adult matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies
por: Dou, Liping, et al.
Publicado: (2019)

Ruxolitinib for myelofibrosis
por: GU, LIAN, et al.
Publicado: (2013)

Impact of Albumin and Omeprazole on Steady-State Population Pharmacokinetics of Voriconazole and Development of a Voriconazole Dosing Optimization Model in Thai Patients with Hematologic Diseases
por: Khan-asa, Buddharat, et al.
Publicado: (2020)

Comparison of modified corneal cross-linking with intrastromal voriconazole for the treatment of fungal corneal ulcer
por: Chen, Yingxin, et al.
Publicado: (2021)

Hematological Toxicity During Concomitant Treatment With Ruxolitinib and Avelumab for Merkel Cell Carcinoma
por: Buonerba, Luciana, et al.
Publicado: (2020)

Comparing Invasive Pulmonary Aspergillosis Mortality Between Liposomal Amphotericin B and Voriconazole in Patients With Hematological Malignancy or Hematopoietic Stem Cell Transplantation
por: Mahmoud, Ebrahim, et al.
Publicado: (2022)

Ruxolitinib combined with vorinostat suppresses tumor growth and alters metabolic phenotype in hematological diseases
por: Civallero, Monica, et al.
Publicado: (2017)

Ruxolitinib for severe fever with thrombocytopenia syndrome (SFTS)
por: Wen, Sai, et al.
Publicado: (2022)

Voriconazole-induced Myositis in a Double Lung Transplant Recipient
por: Soliman, Mohanad, et al.
Publicado: (2019)

Factors Affecting Voriconazole Trough Concentration and Optimal Maintenance Voriconazole Dose in Chinese Children
por: Zhao, Yi-Chang, et al.
Publicado: (2021)

Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies
por: Sekhri, Rohit, et al.
Publicado: (2021)

Impact of CYP2C19 Polymorphisms on Serum Concentration of Voriconazole in Iranian Hematological Patients
por: Ebrahimpour, Sholeh, et al.
Publicado: (2017)

Voriconazole associated torsades de pointes in two adult patients with haematological malignancies
por: Brown, Jeremy D., et al.
Publicado: (2014)

Fatal Disseminated Mucormycosis in a Hematological Immunocompromised Patient with Extensive Voriconazole Exposure: A Case Report and Review of the Literature
por: Humphrey, Victoria S., et al.
Publicado: (2020)

Comparative study of prophylaxis with high and low doses of voriconazole in children with malignancy
por: L. Kandaurava, Sviatlana, et al.
Publicado: (2020)

Empirical voriconazole therapy for febrile neutropenic patients with hematological disorders: a prospective multicenter trial in Japan
por: Koh, Hideo, et al.
Publicado: (2013)

Ferroptosis in hematological malignant tumors
por: Liu, Yong, et al.
Publicado: (2023)

Haematologic malignancies with unfavourable gene mutations benefit from donor lymphocyte infusion with/without decitabine for prophylaxis of relapse after allogeneic HSCT: A pilot study
por: Zhang, Rui, et al.
Publicado: (2021)

Global burden of hematologic malignancies and evolution patterns over the past 30 years
por: Zhang, Nan, et al.
Publicado: (2023)

Ruxolitinib: Thrombocytopenia following compassionate use of ruxolitinib: 2 case reports
Publicado: (2022)

A bibliometric analysis of the research on hematological tumor microenvironment
por: Chen, Peng, et al.
Publicado: (2021)

Response of chromoblastomycosis to voriconazole
por: de Lima, Alexandre Moretti, et al.
Publicado: (2016)

Ruxolitinib for essential thrombocythemia?
por: Bose, Prithviraj, et al.
Publicado: (2017)

Primary hematological malignancy of the uterine cervix: A case report
por: Gui, Wei, et al.
Publicado: (2019)

Dose-escalating ruxolitinib for refractory hemophagocytic lymphohistiocytosis
por: Song, Yue, et al.
Publicado: (2023)

Arginase: Mechanisms and Clinical Application in Hematologic Malignancy
por: Du, Zefan, et al.
Publicado: (2022)

Characteristics of pathogens detected in adults with hematological malignancies and nosocomial infections in the tropics
por: Dou, Li-Ping, et al.
Publicado: (2020)

Effects of Voriconazole on the Pharmacokinetics of Vonoprazan in Rats
por: Shen, Jiquan, et al.
Publicado: (2020)

Semaphorins and Their Receptors in Hematological Malignancies
por: Wei, Li, et al.
Publicado: (2019)

Therapeutic Effect of Intrastromal Voriconazole, Topical Voriconazole, and Topical Natamycin on Fusarium Keratitis in Rabbit
por: Nejabat, Mahmood, et al.
Publicado: (2016)

Ruxolitinib early administration reduces acute GVHD after alternative donor hematopoietic stem cell transplantation in acute leukemia
por: Zhang, Binglei, et al.
Publicado: (2021)

Intracranial blastomycotic abscess mimicking malignant brain neoplasm: Successful treatment with voriconazole and surgery
por: Arora, Kanika, et al.
Publicado: (2015)

Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies
por: Gong, Xiaohua, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_u2hd6j497mljqlr6nt6u8f40o9